… that lung cancers harboring constitutively active mutant EGFR … or growth inhibitory activities
of EGFR TKIs strongly supports the so… with NSCLC who could benefit from EGFR TKI therapy. …

… EGFR TKIs improve response rates, time to progression, and overall survival. … EGFR mutant
lung cancer develop disease progression after a median of 10 to 14 months on EGFR TKI. …

… Tissue from emerging or progressing brain metastases in patients receiving EGFR TKI
therapy rarely demonstrate T790M resistance mutations, which is consistent with a …

… patients with EGFR-mutant lung cancer and acquired resistance to EGFR-TKI therapies that
… Our findings indicate that second-site EGFR T790M mutations are the dominant mechanism …

… of all cancer deaths worldwide. Non-small cell lung cancer (NSCLC) constitutes over 80%
of lung cancer … to combat lung cancer. The development of epidermal growth factor receptor (…

… scientific literature and evidence of EGFR TKIs as first-line therapy from the first-generation
EGFR TKIs to conceptually proposed fourth-generation EGFR TKI, and also recommend the …

… Areas covered: Almost all patients treated with EGFR TKIs … EGFR pathway enhances
susceptibility of the lung tumors to … with EGFR TKIs may be a promising therapeutic strategy. …

… Our pooled analysis of EGFR-TKI treatment in EGFR mutation-positive NSCLC patients
found that the frequency of all-grade ILD in Asian and non-Asian studies was 2.5% and 0.9%, …

… in nonsmoking patients with non-small cell lung cancer (NSCLC). However, this does not …
for EGFR mutations. Our case–control study revealed that lung cancers harbouring EGFR …

… –small cell lung cancer harboring activating mutations of the EGFR gene. We examined the
effects of EGFR tyrosine kinase inhibitor (TKI) therapy in such patients on the tumor immune …